2024
Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomes
2013
The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial
Martin P, DiLiberto M, Mason C, Ely S, Ruan J, Furman R, Chiron D, Huang X, Madoff D, Navi J, Lewis J, Bender A, Rodriguez A, Greenberg J, Coleman M, Chen-Kiang S, Leonard J. The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial. Blood 2013, 122: 4393. DOI: 10.1182/blood.v122.21.4393.4393.Peer-Reviewed Original ResearchMantle cell lymphomaTreatment-related grade 3Dose level 3Dose level 4Dose level 1Phase I trialCombination of palbociclibGrade 3Day 8MCL cellsI trialCell lymphomaDose levelsCyclin D1Seattle GeneticsAdequate bone marrowDose level 2Dose of palbociclibNon-hematologic toxicitiesGrade 4 neutropeniaNausea/vomitingSpeakers bureauDuration of responseCycle 2Novel therapeutic combinations